These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26739236)

  • 1. BAP1/ASXL1 recruitment and activation for H2A deubiquitination.
    Sahtoe DD; van Dijk WJ; Ekkebus R; Ovaa H; Sixma TK
    Nat Commun; 2016 Jan; 7():10292. PubMed ID: 26739236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.
    Daou S; Hammond-Martel I; Mashtalir N; Barbour H; Gagnon J; Iannantuono NV; Nkwe NS; Motorina A; Pak H; Yu H; Wurtele H; Milot E; Mallette FA; Carbone M; Affar el B
    J Biol Chem; 2015 Nov; 290(48):28643-63. PubMed ID: 26416890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.
    Thomas JF; Valencia-Sánchez MI; Tamburri S; Gloor SL; Rustichelli S; Godínez-López V; De Ioannes P; Lee R; Abini-Agbomson S; Gretarsson K; Burg JM; Hickman AR; Sun L; Gopinath S; Taylor HF; Sun ZW; Ezell RJ; Vaidya A; Meiners MJ; Cheek MA; Rice WJ; Svetlov V; Nudler E; Lu C; Keogh MC; Pasini D; Armache KJ
    Sci Adv; 2023 Aug; 9(32):eadg9832. PubMed ID: 37556531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial and Somatic
    Peng H; Prokop J; Karar J; Park K; Cao L; Harbour JW; Bowcock AM; Malkowicz SB; Cheung M; Testa JR; Rauscher FJ
    Cancer Res; 2018 Mar; 78(5):1200-1213. PubMed ID: 29284740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retracted: Histone H2B ubquitination regulates retinoic acid signaling through the cooperation of ASXL1 and BAP1.
    Lee SW; Youn H; Kim EJ; Um SJ
    Mol Cell; 2013 Jul; 51(2):200-10. PubMed ID: 23850490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation.
    Campagne A; Lee MK; Zielinski D; Michaud A; Le Corre S; Dingli F; Chen H; Shahidian LZ; Vassilev I; Servant N; Loew D; Pasmant E; Postel-Vinay S; Wassef M; Margueron R
    Nat Commun; 2019 Jan; 10(1):348. PubMed ID: 30664650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of BAP1 function leads to EZH2-dependent transformation.
    LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
    Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Basis for the Activation of the Deubiquitinase Calypso by the Polycomb Protein ASX.
    De I; Chittock EC; Grötsch H; Miller TCR; McCarthy AA; Müller CW
    Structure; 2019 Mar; 27(3):528-536.e4. PubMed ID: 30639226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basis of the H2AK119 specificity of the Polycomb repressive deubiquitinase.
    Ge W; Yu C; Li J; Yu Z; Li X; Zhang Y; Liu CP; Li Y; Tian C; Zhang X; Li G; Zhu B; Xu RM
    Nature; 2023 Apr; 616(7955):176-182. PubMed ID: 36991118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase.
    Peng H; Cassel J; McCracken DS; Prokop JW; Sementino E; Cheung M; Collop PR; Polo A; Joshi S; Mandell JP; Ayyanathan K; Hinds D; Malkowicz SB; Harbour JW; Bowcock AM; Salvino J; Kennedy EJ; Testa JR; Rauscher FJ
    Mol Cancer Res; 2021 Jul; 19(7):1099-1112. PubMed ID: 33731362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1.
    Daou S; Barbour H; Ahmed O; Masclef L; Baril C; Sen Nkwe N; Tchelougou D; Uriarte M; Bonneil E; Ceccarelli D; Mashtalir N; Tanji M; Masson JY; Thibault P; Sicheri F; Yang H; Carbone M; Therrien M; Affar EB
    Nat Commun; 2018 Oct; 9(1):4385. PubMed ID: 30349006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
    Fukuda T; Tsuruga T; Kuroda T; Nishikawa H; Ohta T
    Curr Cancer Drug Targets; 2016; 16(2):101-9. PubMed ID: 26517537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
    Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
    Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome.
    Srivastava A; Ritesh KC; Tsan YC; Liao R; Su F; Cao X; Hannibal MC; Keegan CE; Chinnaiyan AM; Martin DM; Bielas SL
    Hum Mol Genet; 2016 Feb; 25(3):597-608. PubMed ID: 26647312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1.
    Zhang Y; Koppula P; Gan B
    Cell Cycle; 2019 Apr; 18(8):773-783. PubMed ID: 30907299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer.
    Tsuboyama N; Szczepanski AP; Zhao Z; Wang L
    Genome Biol; 2022 Sep; 23(1):206. PubMed ID: 36180891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB.
    Scheuermann JC; de Ayala Alonso AG; Oktaba K; Ly-Hartig N; McGinty RK; Fraterman S; Wilm M; Muir TW; Müller J
    Nature; 2010 May; 465(7295):243-7. PubMed ID: 20436459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.
    Wu X; Bekker-Jensen IH; Christensen J; Rasmussen KD; Sidoli S; Qi Y; Kong Y; Wang X; Cui Y; Xiao Z; Xu G; Williams K; Rappsilber J; Sønderby CK; Winther O; Jensen ON; Helin K
    Cell Res; 2015 Nov; 25(11):1205-18. PubMed ID: 26470845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
    Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
    Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
    Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
    Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.